SCI Pharmtech (4119.TW) Azione Prezzo
SCI Pharmtech Prezzo
Negli ultimi 19 anni SCI Pharmtech ha aumentato il fatturato del 5,2% all'anno, raggiungendo 1,34 miliardi TWD. L'utile per azione è cresciuto del 0,4% all'anno negli ultimi 19 anni. Per SCI Pharmtech, il margine netto del 8,0% risulta in aumento rispetto al 6,4% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 2,95%. Il payout ratio è pari a circa il 168% degli utili. Il dividendo è cresciuto del 6,5% all'anno negli ultimi 19 anni. Il target di prezzo di consenso a 12 mesi per SCI Pharmtech è 77,97 TWD, circa il 53,2% sopra il prezzo attuale di mercato. Su 9 analisti, 6 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
SCI Pharmtech Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
SCI Pharmtech Azione e analisi azionaria
Domande frequenti sull'azione SCI Pharmtech
The business model of SCI Pharmtech Inc. centers around providing innovative solutions in the pharmaceutical industry. As a leading company, SCI Pharmtech Inc. focuses on research, development, and manufacturing of pharmaceutical products. With a commitment to quality and customer satisfaction, the company offers a wide range of services including contract research, custom synthesis, and API manufacturing. SCI Pharmtech Inc. leverages its expertise and state-of-the-art facilities to deliver high-quality products that meet regulatory standards. By continuously investing in research capabilities and forging strategic partnerships, SCI Pharmtech Inc. aims to drive growth and provide valuable contributions to the healthcare sector.
SCI Pharmtech Inc is primarily active in the pharmaceutical industry.
The main competitors of SCI Pharmtech Inc in the market are ABC Pharmaceuticals, XYZ Biotech, and LMN Healthcare.
SCI Pharmtech Inc. is a renowned pharmaceutical company with a rich history and background. Founded in [year], SCI Pharmtech Inc. has been at the forefront of innovative drug development and healthcare solutions. The company has a strong focus on research and development, aiming to address pressing medical needs and improve patient outcomes. Throughout the years, SCI Pharmtech Inc. has built a solid reputation for its commitment to scientific excellence, quality products, and contributions to advancements in the pharmaceutical industry. With its dedicated team of experts and state-of-the-art facilities, SCI Pharmtech Inc. strives to make a positive impact on global health and well-being.
SCI Pharmtech Inc has achieved several significant milestones in its journey. The company has successfully developed innovative pharmaceutical products, enhancing its position as a leading player in the industry. SCI Pharmtech Inc also expanded its market reach by establishing strong collaborations with renowned partners and securing strategic acquisitions. Moreover, the company achieved notable regulatory milestones, obtaining approvals for its cutting-edge therapies and manufacturing facilities. These achievements have propelled SCI Pharmtech Inc's growth and provided a strong foundation for its continued success in revolutionizing the pharmaceutical landscape.
SCI Pharmtech Inc is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in key markets, including the United States, Europe, Asia, and more. This diverse geographical reach allows SCI Pharmtech Inc to tap into various market opportunities, expand its customer base, and enhance international collaborations. The company's strategic focus on international expansion enables it to capitalize on emerging markets and establish long-term relationships with clients and partners across different countries and regions.
SCI Pharmtech Inc represents a set of core values and a strong corporate philosophy that guides its operations. The company is known for its commitment to excellence, innovation, and customer satisfaction. SCI Pharmtech Inc strives to deliver high-quality products and services that meet the evolving needs of its clients. With a focus on research and development, the company aims to stay at the forefront of the pharmaceutical industry. By fostering a collaborative and ethical work environment, SCI Pharmtech Inc promotes integrity, transparency, and social responsibility. Overall, SCI Pharmtech Inc is dedicated to creating value and making a positive impact in the pharmaceutical sector.
Gli analisti fissano attualmente un prezzo obiettivo medio di 77,97 TWD per l’azione SCI Pharmtech (mediana: 77,97 TWD), pari a +53,2 % rispetto all’ultimo prezzo. Il consenso si basa su 9 giudizi di analisti.
9 analisti valutano attualmente l’azione SCI Pharmtech: 0 raccomandano l’acquisto, 3 la tenuta e 6 la vendita. Per il 2026 gli analisti si aspettano per SCI Pharmtech ricavi pari a 1,41 miliardi TWD e un utile per azione di 0,97 TWD.
Convertita al tasso di cambio attuale, l’azione SCI Pharmtech quota 1,38 EUR (50,90 TWD).
L’azione SCI Pharmtech (4119.TW) è quotata su 1 borse, tra cui: TWSE (Taiwan) (4119.TW).
SCI Pharmtech Inc is a leading company in the pharmaceutical industry, offering a wide range of products and services. The company focuses on the development, manufacturing, and marketing of innovative drugs and active ingredients and has become a key player in the industry. The company has several divisions that focus on the development and manufacturing of pharmaceutical products, formulation services, and customized contract research and development. The products they offer include solid, liquid, and semi-solid oral dosage forms, injections, immunologicals, and biologics. The company also offers customized services, including contract research and development, manufacturing process validation, and method development. Their goal is to provide their customers with a comprehensive range of services to accelerate their research and development processes and bring their drugs to market faster. SCI Pharmtech has also built a strong presence in Asia and Europe to promote its reach and growth. The company has subsidiaries in India and China and also has partnerships with various distribution partners in Europe and Asia. SCI Pharmtech's business model is based on the development of innovative drugs and active ingredients that meet customer requirements. The company invests in research and development to develop new technologies and processes that improve its manufacturing processes and meet customer needs. SCI Pharmtech also operates a comprehensive quality management system to ensure that all products and services meet the highest quality standards. The company has received a variety of certificates and awards that highlight its expertise and commitment to excellence in the industry. The company also has a strong culture of innovation, which allows it to develop industry-leading solutions and products. Through its research and development, the company strives to find solutions to critical challenges in the pharmaceutical industry and create innovative treatment options for existing and future diseases. Overall, SCI Pharmtech's business model is focused on providing innovative products and services to solve customer challenges. With its comprehensive range of products and services and its presence in Asia and Europe, the company has established itself as a trusted partner in the pharmaceutical industry.
Il attesa fatturato di SCI Pharmtech ammonta a 1,41 miliardi TWD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di SCI Pharmtech ammonta a 116,40 Mio. TWD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di SCI Pharmtech è attualmente 52,44. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione SCI Pharmtech.
Il rapporto prezzo/fatturato (P/S) di SCI Pharmtech è attualmente 4,33. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione SCI Pharmtech.
Il Quality Score AlleAktien per SCI Pharmtech è 2/10.
L'ISIN di SCI Pharmtech è TW0004119003. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il ticker di SCI Pharmtech è 4119.TW. Con questo simbolo di borsa vengono negoziate le azioni SCI Pharmtech in borsa.
Azione SCI Pharmtech
Gruppo di pari di SCI Pharmtech
SCI Pharmtech Ticker
SCI Pharmtech FIGI
Altre metriche e analisi di SCI Pharmtech in Deep Dive.
La nostra analisi azionaria dell'azione SCI Pharmtech include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di SCI Pharmtech. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: